BREAST CANCER
Tracks
STREAM 1
| Monday, November 8, 2021 |
| 1:00 PM - 2:45 PM |
| STREAM 1 |
Speaker
Elima Jedy Agba
Epidemiology and characterisation of breast cancer in Africa
Dr Mahine Ivanga
Institute of Human Virology
Epidemiology and characterisation of breast cancer in Africa
Carla Barbosa
Pathology/NCCP/breast cancer: status of breast cancer genetic testing in Africa
Millicent Obajimi
TBC
Imaging for early diagnosis and follow-up: how to maximise resources
Prof Hannah Simonds
Stellenbosch University
IN RESOURCE-CONSTRAINED ENVIRONMENTS, WHAT ARE THE "BEST BUYS" IN SYSTEMIC THERAPY FOR EARLY BREAST CANCER?
Abstract
Oncological therapy is a high cost business.
In breast cancer, this is even more notable due to the multiple available lines of therapy. The variables to be considered in a resource-constrained environment are user fees or universal healthcare; generics vs patented drugs; clinical benefit and most importantly equitable access.
We will review the clinical benefit of hormonal and systemic therapies; tools to assist in decision-making and evidence from health economic data.
In breast cancer, this is even more notable due to the multiple available lines of therapy. The variables to be considered in a resource-constrained environment are user fees or universal healthcare; generics vs patented drugs; clinical benefit and most importantly equitable access.
We will review the clinical benefit of hormonal and systemic therapies; tools to assist in decision-making and evidence from health economic data.
Dr Fatima Cardoso
ABC Global Alliance
Current management of triple negative breast cancer
Prof Papa Macoumba Gaye
Université Cheikh Anta Diop de Dakar
Q&A
Facilitators
Judith Didi-Kouko Coulibaly
Papa Macoumba Gaye
Université Cheikh Anta Diop de Dakar
